Investigators at the Harbor-UCLA Medical Center and the Miller Children's Hospital-Long Beach Memorial Medical Center propose to continue to participate as a combined unit in the scientific activities of the Childrens Cancer Group (CCG). The applicant is a leading CCG institution in entries onto therapeutic studies including first line, second line, and new agent studies. In addition, we are a leading institution in entries onto special studies including epidemiologic studies, pharmacology studies, and other studies either immunologic or supportive in nature. The applicant is supervising over 800 children in active follow- up. Our scientific priorities include CCG trials of treatment, procedures, and management strategies with the objective to place eligible patients on trials of new therapeutic agents. The applicant is one of a select group of CCG institutions approved to conduct limited institutional Phase I and Phase II studies. We have developed and are committed to continue to develop studies which will be the basis of CCG nationwide protocols. We intend to continue to commit our resources to the committee structure of CCG including leadership roles in Strategy Groups, protocol design, and clinical study follow-up, as well as administrative responsibilities. We are committed to continue to contribute with a network of affiliates including Valley Children's Hospital, Cedars Sinai Medical Center, Phoenix Children's Hospital, and University of California, Irvine. There is a strong psychosocial program dedicated to support the child and his/her family with strong emphasis on school reintegration. The program is organized in a multi-disciplinary manner with pediatric oncologists, surgeons, radiotherapists, pathologists, immunologists, and geneticists committed to cooperate with CCG in the concept, design, conduct, analysis, and the reporting of clinical investigations of children with cancer. Pediatric hematologists and oncologists supervise the direct patient care and recording of data by a trained data managerial staff. Results are forwarded to the Childrens Cancer Group Operation's Office for compilation and statistical analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014560-27
Application #
6124413
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
1976-12-01
Project End
2002-11-30
Budget Start
2000-01-17
Budget End
2000-11-30
Support Year
27
Fiscal Year
2000
Total Cost
$163,385
Indirect Cost
Name
La Biomed Research Institute/ Harbor UCLA Medical Center
Department
Type
DUNS #
069926962
City
Torrance
State
CA
Country
United States
Zip Code
90502
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Meyers, P A; Krailo, M D; Ladanyi, M et al. (2001) High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 19:2812-20
Sposto, R; Meadows, A T; Chilcote, R R et al. (2001) Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group. Med Pediatr Oncol 37:432-41

Showing the most recent 10 out of 14 publications